- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07782359
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib (NSCLC)
Impact of Tirzepatide on Lorlatinib-Associated Weight Gain and Metabolic Derangements in Patients With Non-Small Cell Lung Cancer (NSCLC)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Clinical Trials Intake Intake
- Telefonnummer: 855-702-8222
- E-post: cancerclinicaltrials@bsd.uchicago.edu
Studieorter
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- University Of Chicago Medicine Comprehensive Cancer Center
-
Kontakt:
- Clinical Trials Intake
- Telefonnummer: 855-702-8222
- E-post: cancerclinicaltrials@bsd.uchicago.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years
- Receiving lorlatinib as first-line treatment for advanced NSCLC ALK-positive, already prescribed and administered by the patient's treating oncologist as standard of care at the time of study enrollment. This study does not initiate lorlatinib therapy or assign lorlatinib dosing; participants must already be receiving lorlatinib prior to enrollment
Exclusion Criteria:
- Known hypersensitivity to GLP-1 agonists.
- Active, unstable psychiatric illness; current suicidal ideation
- Severe organ dysfunction or systemic illness.
- Anorexia nervosa
- History of pancreatitis
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Current use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) or glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [GLP-1 RA/GIP] co-agonist use within the last 90 days prior to screening
- Current anti-obesity medication use (other than GLP-1 RA) or dipeptidyl peptidase-4 (DPP4) inhibitor use or use within the last 30 days prior to screening
- Pregnant, breastfeeding or planning pregnancy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Tirzepatide Treatment
Individuals taking with an body mass index (BMI) in obese range (BMI greater than or equal to 30) or those with a BMI greater than or equal to 27 and with cardiac risk factors will receive tirzepatide starting after study enrollment. Individuals that do not meet these BMI criteria will start tirzepatide if they experience weight gain of 5% of more during the study. Statistical analysis will include all participants that receive tirzepatide on this study. |
Participants will receive tirzepatide with weekly subcutaneous injections at 2.5 mg, following a structured dose escalation protocol over 20 weeks to reach the target dose of 15 mg per week or the maximum tolerated dose.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Body weight changes
Tidsram: 1 year post treatment start
|
To assess the effect of tirzepatide, on change in body weight in patients taking lorlatinib.
|
1 year post treatment start
|
|
Lipid changes
Tidsram: 1 year post treatment start
|
To assess the effect of tirzepatide on change in lipid profile High-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides) at 52 weeks compared to baseline.
|
1 year post treatment start
|
|
Change in Cmax
Tidsram: 1 year post treatment start
|
Determine if the peak concentration of Lorlatinib is significantly altered when co-administered with tirzepatide.
|
1 year post treatment start
|
|
Change in Tmax
Tidsram: 1 year post treatment start
|
Assess if the time to peak concentration is delayed due to tirzepatide's effect on gastric emptying.
|
1 year post treatment start
|
|
Bioavailability
Tidsram: 1 year post treatment start
|
Evaluate partial AUC to estimate the extent of drug absorption.
|
1 year post treatment start
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of metabolic side effects
Tidsram: 1 year from start of treatment
|
Number of Common Terminology Criteria for Adverse Events (CTCAE) Grade 1-3 metabolic side effects
|
1 year from start of treatment
|
|
Changes in body mass composition
Tidsram: 1 year from start of treatment
|
Changes in body mass will be measured using Bioelectrical Impedance Analysis (BIA).
|
1 year from start of treatment
|
|
Changes in waist circumference
Tidsram: 1 year from start of treatment
|
1 year from start of treatment
|
|
|
Changes in cardiometabolic markers
Tidsram: 1 year from start of treatment
|
The number of participants that experience a change in cardiometabolic markers will be reported.
This includes changes in blood tests for any of the following: Hemoglobin A1c (HbA1c), insulin, glucose, Apolipoprotein B (ApoB), homocysteine, C-reactive protein (CRP), and lipoprotein(a) (Lp(a))
|
1 year from start of treatment
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Marina Garassino, University of Chicago
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Luftvägssjukdomar
- Lungsjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Lungneoplasmer
- Aminosyror, peptider och proteiner
- Proteiner
- Glukagonliknande peptid-1-receptor
- Glukagonliknande peptidreceptorer
- Receptorer, G-proteinkopplad
- Receptorer, cellytan
- Membranproteiner
- Receptorer, gastrointestinalt hormon
- Receptorer, peptid
- Tirzepatid
Andra studie-ID-nummer
- IRB25-1926
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .